Mineralys Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 12, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 12, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| MINERALYS THERAPEUTICS, INC. | |||
| Date: | February 12, 2025 | By: | /s/ Jon Congleton |
|---|---|---|---|
| Jon Congleton | |||
| Chief Executive Officer | |||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons in the capacities held on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Jon Congleton | Chief Executive Officer (Principal Executive Officer) | February 12, 2025 |
| Jon Congleton | ||
| /s/ Adam Levy | Chief Financial Officer and Secretary(Principal Financial and Accounting Officer) | February 12, 2025 |
| Adam Levy | ||
| /s/ Glenn Sblendorio | Chairman | February 12, 2025 |
| Glenn Sblendorio | ||
| /s/ Srinivas Akkaraju | Director | February 12, 2025 |
| Srinivas Akkaraju, M.D., Ph.D. | ||
| /s/ Derek DiRocco | Director | February 12, 2025 |
| Derek DiRocco, Ph.D. | ||
| /s/ Alexander M. Gold | Director | February 12, 2025 |
| Alexander M. Gold, M.D. | ||
| /s/ Daphne Karydas | Director | February 12, 2025 |
| Daphne Karydas | ||
| /s/ Brian Taylor Slingsby | Director | February 12, 2025 |
| Brian Taylor Slingsby, M.D., Ph.D., M.P.H. | ||
– 111 –
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.